A large-scale Mendelian randomization study found no genetic evidence that vitamins A, C, or D reduce the risk of major ...

In the latest trading session, Synopsys (SNPS) closed at $536.52, marking a -2.23% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.79%. Elsewhere, the Dow ...

Synopsys (SNPS) shares closed more than 4% higher on Thursday, July 3 following the White House’s decision to lift restrictions on export of chip-design software to China. Investors are reading the ...

Human genotyping has never been hotter, and a sophisticated set of array-based tools now simplifies the process dramatically, facilitating everything from small basic research studies to complex ...

Synopsys is set for a faster rebound due to China sales resuming, an $8B backlog, and strong AI-driven tool demand. Click ...

Synopsys shares gained after the White House lifted restrictions on export of chip-design software to China. Berenberg analysts believe SNPS shares could hit $600 in the coming months. Synopsys ...

With the recent completion of the Perlegen–US National Institute of Environmental Health Sciences mouse resequencing project 1, which adds 8 million single nucleotide polymorphisms (SNPs) to the ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to states, the federal government, and taxpayers through strategic use of D-SNP ...